Artiva Biotherapeutics (ARTV) Income from Continuing Operations (2023 - 2026)
Artiva Biotherapeutics' (ARTV) quarterly Income from Continuing Operations came in at 35198000.0 in Q1 2026, up 4.46% year-on-year from 33695289.42 in Q1 2025, and down 66.17% on a QoQ basis from 21182000.0 in Q4 2025.
Artiva Biotherapeutics (ARTV) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Artiva Biotherapeutics (ARTV) has 4 years of Income from Continuing Operations data on file, last reported at 35198000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 4.46% year-over-year to 35198000.0 in Q1 2026; TTM through Mar 2026 was 116492000.0, a 4.44% increase from a year earlier, with the FY2025 full-year figure at 87730000.0, down 41.86% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 35198000.0, down from 21182000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for ARTV reached as high as 11229000.0 in Q3 2023 and fell as low as 36841000.0 in Q1 2025.
- Historically, Income from Continuing Operations has averaged 21993333.33 across 4 years, with a median of 23286000.0 in 2024.
- Across the five-year window, Income from Continuing Operations sank 400.97% in 2024 and jumped 30.87% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 11601000.0 in 2023, then tumbled by 100.05% to 23208000.0 in 2024, then climbed by 8.73% to 21182000.0 in 2025, then tumbled by 66.17% to 35198000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 35198000.0 in Q1 2026, 21182000.0 in Q4 2025, and 23364000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Artiva Biotherapeutics | 249.99 Mn | 249.99 Mn | - | -35.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.20 Mn |
| Dec 31, 2025 | -21.18 Mn |
| Sep 30, 2025 | -23.36 Mn |
| Jun 30, 2025 | -36.75 Mn |
| Mar 31, 2025 | -36.84 Mn |
| Dec 31, 2024 | -23.21 Mn |
| Sep 30, 2024 | -33.80 Mn |
| Jun 30, 2024 | -28.05 Mn |
| Mar 31, 2024 | -13.84 Mn |
| Dec 31, 2023 | -11.60 Mn |
| Sep 30, 2023 | 11.23 Mn |
| Jun 30, 2023 | -11.32 Mn |